Welcome to our dedicated page for Neurogene SEC filings (Ticker: NGNE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Neurogene's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Neurogene's regulatory disclosures and financial reporting.
On August 11, 2025, Neurogene Inc. reported that it issued a press release announcing financial results for the quarter ended June 30, 2025 and posted an updated corporate presentation on its website. The Form 8-K attaches Exhibit 99.1 (press release) and Exhibit 99.2 (corporate presentation) and states these exhibits are being furnished, not filed, so they are not subject to Section 18 liabilities or deemed incorporated by reference. The filing text does not include the actual earnings figures; the report is signed by Christine Mikail, President and Chief Financial Officer.